Virtu Financial LLC Fibrogen Inc Transaction History

Virtu Financial LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 17, 2022	SELL	$9.93 - $15.39 $115,525 - $179,047	-11,634 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$10.18 - $26.64 $118,434 - $309,929	11,634 New	11,634 $119,000
Q1 2021 May 19, 2021	SELL	$31.0 - $55.72 $223,541 - $401,796	-7,211 Closed	0 $0
Q4 2020 Feb 24, 2021	SELL	$37.09 - $48.97 $189,381 - $250,040	-5,106 Reduced 41.45%	7,211 $267,000
Q3 2020 Dec 11, 2020	BUY	$40.47 - $45.5 $137,314 - $154,381	3,393 Added 38.02%	12,317 $506,000
Q2 2020 Aug 07, 2020	SELL	$32.57 - $42.83 $52,372 - $68,870	-1,608 Reduced 15.27%	8,924 $362,000
Q4 2019 Feb 04, 2020	BUY	$34.58 - $48.06 $161,454 - $224,392	4,669 Added 79.63%	10,532 $452,000
Q3 2019 Nov 20, 2019	BUY	$36.98 - $48.45 $216,813 - $284,062	5,863 New	5,863 $217,000
Q2 2019 Aug 13, 2019	SELL	$35.13 - $55.53 $248,720 - $393,152	-7,080 Closed	0 $0
Q1 2019 Apr 12, 2019	SELL	$42.83 - $59.91 $29,895 - $41,817	-698 Reduced 8.97%	7,080 $385,000
Q1 2018 May 14, 2018	BUY	$45.35 - $61.65 $352,732 - $479,513	7,778 New	7,778 $359,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.